<DOC>
	<DOC>NCT00903383</DOC>
	<brief_summary>The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX3305 versus a placebo control in subjects with active rheumatoid arthritis on stable methotrexate therapy.</brief_summary>
	<brief_title>Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Males and females aged 1875 years old Rheumatoid arthritis present for at least 6 months, functional class I, II, or III as defined by ACR criteria Active disease as determined by the presence of ≥6 swollen joints, ≥6 tender joints, and serum Creactive protein level &gt; upper limit of normal Receiving stable dose of MTX (≥10 mg/wk) and folate supplementation at least 8 weeks prior to Day 1 Ability to provide written informed consent RA diagnosis prior to 16 years of age (Juvenile RA) Lack of response to &gt;3 disease modifying antirheumatic drugs (DMARDs) or exposure to &gt;1 biologic DMARD Use of DMARDs other than MTX within 12 weeks prior to Day 1 Intraarticular and/or parenteral corticosteroids within 4 weeks prior to study Day 1 Blood donation or receipt of live vaccine within 4 weeks prior to Day 1 Major surgical procedure within 8 weeks prior to Day 1 Any systemic inflammatory condition, recurrent infection, or current infection other than onychomycosis History of cancer within 5 years prior to Day 1 Presence of hepatic or biliary disease History of tuberculosis History of human immunodeficiency virus (HIV)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>